Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05760898 · ClinicalTrials.gov registry record · NA

Improving Hypertension Control in Rheumatoid Arthritis

A NA study of Hypertension and Rheumatoid Arthritis, sponsored by Duke University.

Recruiting
Registry status
NA
Development phase
25
Enrollment target
1
Study location

NCT05760898 is a NA study of Hypertension and Rheumatoid Arthritis that is actively recruiting participants, run by Duke University. The registered enrollment target is 25 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05760898, a NA study of Hypertension and Rheumatoid Arthritis, is actively recruiting participants, sponsored by Duke University.

RECRUITING
Registry status
NA
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

Rheumatoid arthritis (RA) is a autoimmune disease associated with an increased risk of developing coronary artery disease (CAD) and premature death,. Traditional CAD risk factors like hypertension (HTN) are both very common and poorly controlled among RA patients. Patients with RA face significant challenges in controlling HTN. The goal of this project is to identify barriers to HTN care in patients with RA to reduce CAD events.

Interventions

  • BEHAVIORAL Blood pressure intervention arm

Study Locations (1)

North Carolina

  • Duke Health System - Durham

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2026-01-16
Est. Completion 2026-12-31
Phase NA

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT05760898

The ClinicalTrials.gov registry entry for NCT05760898 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (99% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Blood pressure intervention arm is the first listed.

NCT05760898 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT05760898 about?

NCT05760898 is a clinical study titled "Improving Hypertension Control in Rheumatoid Arthritis". Rheumatoid arthritis (RA) is a autoimmune disease associated with an increased risk of developing coronary artery disease (CAD) and premature death,. Traditional CAD risk factors like hypertension (HTN) are both very common and poorly controlled among RA patients. Patients with RA face significant c...

What is the current status of trial NCT05760898?

This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2026-01-16. Estimated completion is 2026-12-31.

What conditions does trial NCT05760898 study?

This clinical trial studies the following conditions: Hypertension, Rheumatoid Arthritis.

What interventions are being tested in trial NCT05760898?

The interventions under investigation include: Blood pressure intervention arm (BEHAVIORAL).

Who is sponsoring clinical trial NCT05760898?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05760898 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.